狭窄大血管参与巨细胞动脉炎的预后和长期结果
Georgina Maalouf1, Bérangère Arnould2, Olivier Espitia3
1Sorbonne Universités AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Département de Médecine Interne et immunologie Clinique, F-75013, Paris , France , Centre National de Références Maladies Autoimmunes Systémiques Rares, Centre National de Références Maladies Autoinflammatoires et Amylose Inflammatoire ( CEREMAIA) ; Inflammation-Immunopathology-Biotherapy Department (DMU 3iD) ; CIC Biotherapy ; INSERM 959, Groupe Hospitalier Pitié Salpetriere, AP-HP, Paris, France.
Arthritis & rheumatology (Hoboken, N.J.)
|February 23, 2026
概括
巨细胞动脉炎 (GCA) 与大血管血管炎 (LVV) 狭窄性参与,影响不到10%的患者,与不良的血管结局有关. 年龄和脊椎动脉狭窄是并发症的关键风险因素.
科学领域:
- 血管医学 血管医学
- 类风湿病学 类风湿病学
- 内部医学 内部医学
背景情况:
- 巨细胞动脉炎 (GCA) 是大型血管血管炎 (LVV) 的一种常见形式.
- 在GCA-LVV中,狭窄性参与的理解较少.
- 评估GCA与狭窄性LVV的结果对于患者管理至关重要.
研究的目的:
- 评估GCA患者的长期预后,这些患者患有狭窄性大血管血管炎 (LVV).
- 在这个患者群体中确定与血管并发症相关的因素.
主要方法:
- 对3,149名GCA患者的回顾性分析,其中198人患有狭窄性LVV.
- 对动脉定位模式的主要组件 (HCPC) 进行分层聚类.
- 后勤回归用于确定血管并发症的风险因素.
主要成果:
- 狭窄性LVV主要影响关节下 (63%),大脑动脉 (58%) 和脊椎动脉 (37%).
- 主要并发症包括中风 (31%) 和肢体缺血 (21%).
- 10年后,累积血管并发症发生率达到19.5%. 年龄和脊椎干扰独立地预测了更糟糕的结果.
结论:
- 狭窄性LVV代表了GCA的一个小但重要的子集 (<10%).
- 这个子组面临着不良的血管预后.
- 早期识别和监测风险因素,如年龄和脊椎狭窄,至关重要.
相关概念视频
Aneurysm III: Interprofessional Care
365
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
365
Aortic Regurgitation III: Medical Management
499
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
499
Atherosclerosis III: Management
476
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476


